A5089759350- Mobile Health and mHealth Applications
- Lipoproteins and Cardiovascular Health
- Health Promotion and Cardiovascular Prevention
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Genetic and phenotypic traits in livestock
- Pharmaceutical studies and practices
- Cardiac Health and Mental Health
- Cardiovascular Health and Risk Factors
- Child and Adolescent Health
- Antiplatelet Therapy and Cardiovascular Diseases
- Medicinal Plant Pharmacodynamics Research
- Genetic diversity and population structure
- Physical Activity and Health
- Venous Thromboembolism Diagnosis and Management
- Acute Myocardial Infarction Research
- Genetic factors in colorectal cancer
- Cancer-related molecular mechanisms research
- Wildlife Ecology and Conservation
- Healthcare Systems and Public Health
Biotechnology Research Center
2021
Kiel University
1998
Abstract Background Heterozygous familial hypercholesterolemia (FH) represents the most frequent monogenic disorder with an estimated prevalence of 1:250 in general population. Diagnosis during childhood enables early initiation preventive measures, reducing risk severe consecutive atherosclerotic manifestations. Nevertheless, population-based screening programs for FH are scarce. Methods In VRONI study, children aged 5–14 years Bavaria invited to participate program regular pediatric...
Mobile health (mHealth) apps can be used for cardiovascular disease (CVD) prevention. User-centered design, evidence-based content and user testing applied to ensure a high level of usability adequate app access.
Identifying high-risk individuals is crucial for preventing cardiovascular diseases (CVDs). Currently, risk assessment mostly performed by physicians. Mobile health apps could help decouple the determination of from medical resources allowing unrestricted self-assessment. The respective test results need to be interpretable laypersons.Together with a patient organization, we aimed design digital calculator that allows people individually assess and optimize their CVD risk. was integrated...
Abstract Familial hypercholesterolemia (FH) is the most frequent monogenic disorder (prevalence 1:250) in general population. Early diagnosis during childhood enables pre-emptive treatment, thus reducing risk of severe atherosclerotic manifestations later life. Nonetheless, FH screening programs are scarce. VRONI offers all children aged 5–14 years Bavaria a context regular pediatric visits. LDL-cholesterol (LDL-C) measured centrally, followed by genetic analysis for if exceeding...
<sec> <title>BACKGROUND</title> Identifying high-risk individuals is crucial for preventing cardiovascular diseases (CVDs). Currently, risk assessment mostly performed by physicians. Mobile health apps could help decouple the determination of from medical resources allowing unrestricted self-assessment. The respective test results need to be interpretable laypersons. </sec> <title>OBJECTIVE</title> Together with a patient organization, we aimed design digital calculator that allows people...
Abstract Background: Heterozygous Familial Hypercholesterolemia (FH) represents the most frequent monogenic disorder with an estimated prevalence of 1:250 in general population. Diagnosis during childhood enables early initiation preventive measures, reducing risk severe consecutive atherosclerotic manifestations. Nevertheless, population-based screening programs for FH are scarce. Methods: In VRONI study children aged 5 to 14 years Bavaria invited participate a program regular pediatric...